Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Repare Therapeutics Inc.

< Previous 1 2 Next >
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Regain Global Rights to Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.